Get the Stockscreener App
13.53
2.81%
0.38
Moonlake Immunotherapeutics stock is traded at $13.53, with a volume of 1.42M.
It is up +2.81% in the last 24 hours and up +42.02% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$13.15
Open:
$13.2
24h Volume:
1.42M
Relative Volume:
0.30
Market Cap:
$861.29M
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-5.8826
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
+0.90%
1M Performance:
+42.02%
6M Performance:
-65.27%
1Y Performance:
-75.04%
1-Day Range:
$13.04
$13.54
1-Week Range:
$12.43
$13.99
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
13.52 | 931.64M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.95 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.48 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.87 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.77 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.36 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
DEADLINE ALERT for ATYR, MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Urges Investors of aTyr, Marex, - GlobeNewswire
MoonLake Immunotherapeutics’ (MLTX) Reported Phase 3 Trial - GlobeNewswire
Investors in MoonLake Immunotherapeutics Should Contact The - GlobeNewswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
2025-11-24 | Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action | NDAQ:MLTX | Press Release - Stockhouse
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MoonLake Immunotherapeutics Sued for Securities Law Violations - GuruFocus
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
2025-11-23 | Investors in MoonLake Immunotherapeutics (MLTX): Protect Your RightsContact Levi & Korsinsky Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MLTX INVESTOR REMINDER: Faruqi & Faruqi, LLP Announces that MoonLake Investors Have Opportunity to Lead Class Action Lawsuit - MarketScreener
MLTX COURT ALERT: MoonLake Immunotherapeutics Investors that Lost Money May have been Affected by Fraud -- Contact BFA Law by December 15 - GlobeNewswire
HC Wainwright Lowers MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $26.00 - Defense World
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - Morningstar
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionMLTX - MarketScreener
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - PR Newswire
Moonlake Immunotherapeutics stock price target lowered to $26 at H.C. Wainwright - Investing.com India
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - Nasdaq
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Burned by MoonLake Immunotherapeutics? Contact Levi & Korsinsky to SueWallSt And Fight Back - ACCESS Newswire
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join - GlobeNewswire
MLTX INVESTORS: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses to Contact the Firm Before the Imminent December 15 Securities Class Action Deadline - MarketScreener
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - FinancialContent
MLTX LAWSUIT ALERT: The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
MLTX LEGAL REMINDER: MoonLake Immunotherapeutics Faces Securities Allegations over Drug Trial Results -- Investors Alerted to Contact BFA Law before December 15 - ACCESS Newswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake - GlobeNewswire
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
The Gross Law Firm Notifies MoonLake Immunotherapeutics - GlobeNewswire
MLTX LAWSUIT: MoonLake Immunotherapeutics Investors are Notified to Contact BFA Law about the Filed Securities Fraud Class Action and Important December 15 Deadline - Newsfile
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - The Globe and Mail
Holdings of MoonLake Immunotherapeutics (MLTX) are aligned with the stars - Setenews
MLTX CLASS NOTICE: BFA Law Alerts MoonLake Immunotherapeutics Investors of the Pending Securities Fraud Class Action and Upcoming December 15 Deadline - Newsfile
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action - GuruFocus
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - PR Newswire
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out - Yahoo Finance
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - news.stocktradersdaily.com
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Over Securities ViolationsContact Levi & Korsinsky Today - Newsfile
MLTX DEADLINE REMINDER: MoonLake Immunotherapeutics 90% Stock Drop Triggers Securities Fraud Class ActionInvestors Urged to Contact BFA Law by December 15 - ACCESS Newswire
MLTX MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - MarketScreener
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - GlobeNewswire
MLTX DEADLINE REMINDER: Berger Montague Reminds MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Important Class Action Lawsuit Deadline - Eastern Progress
MoonLake Immunotherapeutics Stock: Ignore The Panic, Catch The Upside (NASDAQ:MLTX) - Seeking Alpha
Bragar Eagel & Squire, P.C. Reminds Stockholders of aTyr, - GlobeNewswire
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chen Bihua | Former 10% Owner |
Sep 29 '25 |
Sale |
7.21 |
6,494,151 |
46,827,628 |
2,000,000 |
| Chen Bihua | Former 10% Owner |
Sep 30 '25 |
Sale |
6.96 |
5,827 |
40,556 |
1,994,173 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Option Exercise |
0.00 |
23,500 |
0 |
23,500 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):